Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients

Histopathology

Volumn 63, Issue 6, 2013, Pages 788-801

  Culpin, Rachel E ^a   Sieniawski, Michal ^a   Angus, Brian ^b   Menon, Geetha K ^b   Proctor, Stephen J ^a   Milne, Paul ^a   Mccabe, Kate ^a   Mainou Fowler, Tryfonia ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

Diffuse large B cell lymphoma; Immunohistochemistry; N HL; Predictive algorithms; Prognosis; Survival

Indexed keywords

CD5 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GCET1 PROTEIN; INTERFERON REGULATORY FACTOR 4; KI 67 ANTIGEN; LMO2 PROTEIN; PREDNISOLONE; PROTEIN; PROTEIN BCL 2; PROTEIN BCL 6; RITUXIMAB; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP1; TUMOR MARKER; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; ALGORITHM; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; COHORT ANALYSIS; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SURVIVAL TIME;

DIFFUSE LARGE B CELL LYMPHOMA; IMMUNOHISTOCHEMISTRY; N-HL; PREDICTIVE ALGORITHMS; PROGNOSIS; SURVIVAL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; DOXORUBICIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; KAPLAN-MEIER ESTIMATE; LIM DOMAIN PROTEINS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEPRILYSIN; PREDNISONE; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SERPINS; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE; YOUNG ADULT;

EID: 84887823331     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12223     Document Type: Article

References (52)

1. Vose JM, Link BK, Grossbard ML et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J. Clin. Oncol. 2001; 19; 389-397.
2. Feugier P, Van Hoof A, Sebban C et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large-B-cell lymphoma: a study by the Groupe d'étude des lymphomes de l'adulte. J. Clin. Oncol. 2005; 23; 4117-4126.
3. Sehn LH, Donaldson J, Chhanabhai M et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J. Clin. Oncol. 2005; 23; 5027-5033.
4. Habermann TM, Weller EA, Morrison VA et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B -cell lymphoma. J. Clin. Oncol. 2006; 24; 3121-3127.
5. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971; 31; 1860-1861.
6. A predictive model for aggressive non-Hodgkin's lymphoma. The international non-Hodgkin's lymphoma prognostic factors project. N. Engl. J. Med. 1993; 329; 987-994.
7. Sehn LH, Berry B, Chhanabhai M et al. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109; 1857-1861.
8. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103; 275-282.
9. Muris JJF, Meijer CJLM, Vos W et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J. Pathol. 2006; 208; 714-723.
10. Choi WWL, Weisenburger DD, Greiner TC et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin. Cancer Res. 2009; 15; 5494-5502.
11. Saez A-I, Saez A-J, Artiga M-J et al. Building an outcome predictor model for diffuse large B-cell lymphoma. Am. J. Pathol. 2004; 164; 613-622.
12. Nyman H, Jerkeman M, Karjalainen-Lindsberg M-L, Banham AH, Leppa S. Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP. Mod. Pathol. 2009; 22; 1094-1101.
13. Meyer PN, Fu K, Greiner TC et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J. Clin. Oncol. 2011; 29; 200-207.
14. Fu K, Weisenburger DD, Choi WWL et al. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J. Clin. Oncol. 2008; 26; 4587-4594.
15. Salles G, de Jong D, Xie W et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood 2011; 117; 7070-7078.
16. de Jong D, Rosenwald A, Chhanabhai M et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications - a study from the Lunenburg Lymphoma Biomarker Consortium. J. Clin. Oncol. 2007; 25; 805-812.
17. Gascoyne RD, Adomat SA, Krajewski S et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997; 90; 244-251.
18. Huang JZ, Sanger WG, Greiner TC et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002; 99; 2285-2290.
19. Hill ME, MacLennan KA, Cunningham DC et al. Prognostic significance of Bcl-2 expression and Bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British national lymphoma investigation study. Blood 1996; 88; 1046-1051.
20. Iqbal J, Sanger WG, Horsman DE et al. Bcl2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am. J. Pathol. 2004; 165; 159-166.
21. Barrans SL, Carter I, Owen RG et al. Germinal center phenotype and Bcl-2 expression combined with the international prognostic index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002; 99; 1136-1143.
22. Barrans SL, Evans PAS, O'Connor SJM et al. The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clin. Cancer Res. 2003; 9; 2133-2139.
23. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403; 503-511.
24. Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 2002; 346; 1937-1947.
25. Visco C, Li Y, Xu-Monette ZY et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the international DLBCL Rituximab-CHOP Consortium Program study. Leukemia 2012; 26; 2103-2113.
26. Nyman H, Adde M, Karjalainen-Lindsberg M-L et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007; 109; 4930-4935.
27. Copie-Bergman C, Gaulard P, Leroy K et al. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a Gela study. J. Clin. Oncol. 2009; 27; 5573-5579.
28. Gutiérrez-García G, Cardesa-Salzmann T, Climent F et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood 2011; 117; 4836-4843.
29. Natkunam Y, Farinha P, Hsi ED et al. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J. Clin. Oncol. 2008; 26; 447-454.
30. Hong J, Park S, Park J et al. Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy. Leuk. Lymph. 2011; 52; 1904-1912.
31. Swerdlow SH, Campo E, Harris NL et al. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. Lyon: IARC Press, 2008.
32. Tzankov A, Zlobec I, Went P, Robl H, Hoeller S, Dirnhofer S. Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. Leuk. Lymph. 2010; 51; 199-212.
33. Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the haematological malignancy research network. Br. J. Cancer 2011; 105; 1684-1692.
34. Kramer MH, Hermans J, Wijburg E et al. Clinical relevance of Bcl2, Bcl6, and Myc rearrangements in diffuse large B-cell lymphoma. Blood 1998; 92; 3152-3162.
35. Sanchez E, Chacon I, Plaza MM et al. Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. J. Clin. Oncol. 1998; 16; 1931-1939.
36. Wilson KS, Sehn LH, Berry B et al. CHOP-R therapy overcomes the adverse prognostic influence of Bcl-2 expression in diffuse large B-cell lymphoma (DLBCL). J. Clin. Oncol. (Meeting Abstracts)2004; 22; 6526.
37. Mounier N, Briere J, Gisselbrecht C et al. Rituximab plus CHOP (R-CHOP) overcomes Bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101; 4279-4284.
38. Johnson NA, Slack GW, Savage KJ et al. Concurrent expression of Myc and Bcl2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J. Clin. Oncol. 2012; 30; 3452-3459.
39. Borlot VF, Biasoli I, Schaffel R et al. Evaluation of intra- and interobserver agreement and its clinical significance for scoring Bcl-2 immunohistochemical expression in diffuse large B-cell lymphoma. Pathol. Int. 2008; 58; 596-600.
40. Seki R, Ohshima K, Fujisaki T et al. Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Sci. 2009; 100; 1842-1847.
41. Reed JC. Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin. Hematol. 1997; 34; 9-19.
42. Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of Bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin. Cancer Res. 2001; 7; 709-723.
43. Green TM, Young KH, Visco C et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J. Clin. Oncol. 2012; 30; 3460-3467.
44. Winter JN, Weller EA, Horning SJ et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006; 107; 4207-4213.
45. Linderoth J, Ehinger M, Åkerman M et al. Tissue microarray is inappropriate for analysis of Bcl6 expression in diffuse large B-cell lymphoma. Eur. J. Haematol. 2007; 79; 146-149.
46. Natkunam Y, Zhao S, Mason DY et al. The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. Blood 2007; 109; 1636-1642.
47. Lossos IS, Czerwinski DK, Alizadeh AA et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N. Engl. J. Med. 2004; 350; 1828-1837.
48. Linderoth J, Jerkeman M, Cavallin-Stahl E, Kvaloy S, Torlakovic E, Nordic Lymphoma Group S. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group study. Clin. Cancer Res. 2003; 9; 722-728.
49. Barrans SL, Fenton JAL, Banham A, Owen RG, Jack AS. Strong expression of FoxP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 2004; 104; 2933-2935.
50. Banham AH, Connors JM, Brown PJ et al. Expression of the FoxP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin. Cancer Res. 2005; 11; 1065-1072.
51. Ott G, Ziepert M, Klapper W et al. Immunoblastic morphology but not the immunohistochemical gcb/nongcb classifier predicts outcome in diffuse large B-cell lymphoma in the ricover-60 trial of the DSHNHL. Blood 2010; 116; 4916-4925.
52. Barrans S, Crouch S, Smith A et al. Rearrangement of myc is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J. Clin. Oncol. 2010; 28; 3360-3365.